Molecular Aspects of Co-morbidities in COVID-19 Infection
نویسندگان
1 Department of Medical Genetics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 1 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2 Department of Medical Genetics, Faculty of Medicine
3 1 Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2 Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
doi
10.22038/abjs.2020.47828.2361چکیده
Coronaviruses are a group of enveloped viruses with single-stranded non-segmented positive-sense RNA genomes. InDecember 2019, SARS-CoV-2 appeared in China for the first time and quickly spread throughout the world. Althoughcertain medications suggested for other afflictions tend to be potentially effective for curing the infection, there is noapproved vaccination or drug available for this virus yet. Comprehension of the disease molecular pathogenesis couldprovide useful tools for COVID-19 patients in surveillance, prognosis, treatment, vaccine development and therapeutictargeting. The present research aims to summarize the association in COVID-19 patients between molecular dimensionsof comorbidities with clinical and preclinical information.Developing an ACE2 inhibitor could be a possible therapeutic target. Plasmin is another possible candidate both indiagnosis and treatment areas. All predicted biomarkers must be validated either through randomized clinical trials orexperimental assays before clinical application in patients.Level of evidence: V
